#BEGIN_DRUGCARD DB01171

# AHFS_Codes:
28:16.04.12

# ATC_Codes:
N06AG02

# Absorption:
Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration.

# Biotransformation:
Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.

# Brand_Mixtures:
Not Available

# Brand_Names:
Aurorix
Manerix

# CAS_Registry_Number:
71320-77-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C13H17ClN2O2

# Chemical_IUPAC_Name:
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2243348

# Description:
A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.

# Dosage_Forms:
Tablet	Oral
Tablet	Oral

# Drug_Category:
Antidepressive Agents
Monoamine Oxidase Inhibitors

# Drug_Interactions:
Amitriptyline	Possible severe adverse reaction with this combination
Amoxapine	Possible severe adverse reaction with this combination
Bezafibrate	MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like moclobemide.
Brimonidine	MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
Buprenorphine	Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
Cimetidine	Cimetidine may increase the serum concentration of moclobemide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moclobemide if cimetidine is initiated, discontinued or dose changed.
Citalopram	Possible serotoninergic syndrome
Clomipramine	Possible severe adverse reaction with this combination
Desipramine	Possible severe adverse reaction with this combination
Desvenlafaxine	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
Dextromethorphan	Increased CNS toxicity
Dobutamine	Moclobemide increases the sympathomimetic effect of dobutamine.
Donepezil	Possible antagonism of action
Dopamine	Moclobemide increases the sympathomimetic effect of dopamine.
Doxepin	Possible severe adverse reaction with this combination
Ephedra	Moclobemide increases the sympathomimetic effect of ephedra.
Ephedrine	Moclobemide increases the sympathomimetic effect of ephedrine.
Epinephrine	Moclobemide increases the sympathomimetic effect of epinephrine.
Fenoterol	Moclobemide increases the sympathomimetic effect of fenoterol.
Fluoxetine	Risk of serotoninergic syndrome
Fluvoxamine	Increased incidence of adverse effects with this association
Galantamine	Possible antagonism of action
Imipramine	Possible severe adverse reaction with this combination
Isoproterenol	Moclobemide increases the sympathomimetic effect of isoproterenol.
Meperidine	Increased CNS toxicity (can cause death)
Mephentermine	Moclobemide increases the sympathomimetic effect of mephentermine.
Metaraminol	Moclobemide increases the sympathomimetic effect of metaraminol.
Methoxamine	Moclobemide increases the sympathomimetic effect of methoxamine.
Milnacipran	Increase serotonin levels. Combination therapy is contraindicated.
Norepinephrine	Moclobemide increases the sympathomimetic effect of norepinephrine.
Nortriptyline	Possible severe adverse reaction with this combination
Orciprenaline	Moclobemide increases the sympathomimetic effect of orciprenaline.
Paroxetine	Possible severe adverse reaction with this combination
Phenylephrine	Moclobemide increases the sympathomimetic effect of phenylephrine.
Phenylpropanolamine	Moclobemide increases the sympathomimetic effect of phenylpropanolamine.
Pirbuterol	Moclobemide increases the sympathomimetic effect of pirbuterol.
Procaterol	Moclobemide increases the sympathomimetic effect of procaterol.
Protriptyline	Possible severe adverse reaction with this combination
Pseudoephedrine	Moclobemide increases the sympathomimetic effect of pseudoephedrine.
Rivastigmine	Possible antagonism of action
Rizatriptan	The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
Salbutamol	Moclobemide increases the sympathomimetic effect of salbutamol.
Selegiline	Decrease in selectivity
Sertraline	Possible severe adverse reaction with this combination
Sibutramine	Possible serotoninergic syndrome with this combination
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Moclobemide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.
Terbinafine	Terbinafine may reduce the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for therapeutic/adverse effects of Moclobemide if Terbinafine is initiated, discontinued or dose changed.
Terbutaline	Moclobemide increases the sympathomimetic effect of terbutaline.
Tetrabenazine	Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated.
Ticlopidine	Ticlopidine may decrease the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for adverse/toxic effects of Moclobemide if Ticlopidine is initiated, discontinued or dose changed.
Tolcapone	Tolcapone and Moclobemide decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
Tramadol	Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide.
Tranylcypromine	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
Trazodone	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimethobenzamide	Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Trimipramine	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
Triprolidine	Triprolidine and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Trospium	Trospium and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Tryptophanyl-5'amp	Possible severe adverse reaction with this combination
Venlafaxine	Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
Zolmitriptan	The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.5

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Food slows absorption a little. Avoid alcohol. Take after meals in order to minimize the risk of interaction with tyramine.

# GenBank_ID:
Not Available

# Generic_Name:
Moclobemide

# HET_ID:
Not Available

# Half_Life:
1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

# InChI_Identifier:
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)

# InChI_Key:
InChIKey=YHXISWVBGDMDLQ-UHFFFAOYSA-N

# Indication:
For the treatment of depression.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02561

# LIMS_Drug_ID:
1171

# Mechanism_Of_Action:
The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
268.739

# Molecular_Weight_Mono:
268.097855505

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1O5W

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA452615

# Pharmacology:
Moclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.

# Predicted_LogP_Hydrophobicity:
1.56

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
1.12e+00 g/l

# Primary_Accession_No:
DB01171

# Protein_Binding:
Approximately 50% (primarily to albumin)

# PubChem_Compound_ID:
4235

# PubChem_Substance_ID:
46504667

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00603

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
4-Chlor-N-(2-morpholinoethyl)benzamid
4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
Moclaime
Moclamide
Moclamine
Moclobemid
Moclobemida [INN-Spanish]
Moclobemide [Usan:Ban:Inn]
Moclobemidum [INN-Latin]
p-Chloro-N-(2-morpholinoethyl)benzamide

# Synthesis_Reference:
Not Available

# Toxicity:
LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures.

# Update_Date:
2013-02-08 16:19:58 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Moclobemide

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
MAOB

# Phase_1_Metabolizing_Enzyme_1_ID:
3939

# Phase_1_Metabolizing_Enzyme_1_Name:
Amine oxidase [flavin-containing] B

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Amine oxidase [flavin-containing] B
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P27338

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
MAOA

# Phase_1_Metabolizing_Enzyme_2_ID:
3941

# Phase_1_Metabolizing_Enzyme_2_Name:
Amine oxidase [flavin-containing] A

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P21397

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_3_ID:
4119

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_4_ID:
4200

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_5_ID:
4757

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_6_ID:
6016

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Mitochondrion

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
1705137	Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16.
8875133	Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 Sep;52(3):450-74.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
MAOA

# Drug_Target_1_GenBank_ID_Gene:
M68840

# Drug_Target_1_GenBank_ID_Protein:
187353

# Drug_Target_1_GeneCard_ID:
MAOA

# Drug_Target_1_Gene_Name:
MAOA

# Drug_Target_1_Gene_Sequence:
>1584 bp
ATGGAGAATCAAGAGAAGGCGAGTATCGCGGGCCACATGTTCGACGTAGTCGTGATCGGA
GGTGGCATTTCAGGACTATCTGCTGCCAAACTCTTGACTGAATATGGCGTTAGTGTTTTG
GTTTTAGAAGCTCGGGACAGGGTTGGAGGAAGAACATATACTATAAGGAATGAGCATGTT
GATTACGTAGATGTTGGTGGAGCTTATGTGGGACCAACCCAAAACAGAATCTTACGCTTG
TCTAAGGAGCTGGGCATAGAGACTTACAAAGTGAATGTCAGTGAGCGTCTCGTTCAATAT
GTCAAGGGGAAAACATATCCATTTCGGGGCGCCTTTCCACCAGTATGGAATCCCATTGCA
TATTTGGATTACAATAATCTGTGGAGGACAATAGATAACATGGGGAAGGAGATTCCAACT
GATGCACCCTGGGAGGCTCAACATGCTGACAAATGGGACAAAATGACCATGAAAGAGCTC
ATTGACAAAATCTGCTGGACAAAGACTGCTAGGCGGTTTGCTTATCTTTTTGTGAATATC
AATGTGACCTCTGAGCCTCACGAAGTGTCTGCCCTGTGGTTCTTGTGGTATGTGAAGCAG
TGCGGGGGCACCACTCGGATATTCTCTGTCACCAATGGTGGCCAGGAACGGAAGTTTGTA
GGTGGATCTGGTCAAGTGAGCGAACGGATAATGGACCTCCTCGGAGACCAAGTGAAGCTG
AACCATCCTGTCACTCACGTTGACCAGTCAAGTGACAACATCATCATAGAGACGCTGAAC
CATGAACATTATGAGTGCAAATACGTAATTAATGCGATCCCTCCGACCTTGACTGCCAAG
ATTCACTTCAGACCAGAGCTTCCAGCAGAGAGAAACCAGTTAATTCAGCGGCTTCCAATG
GGAGCTGTCATTAAGTGCATGATGTATTACAAGGAGGCCTTCTGGAAGAAGAAGGATTAC
TGTGGCTGCATGATCATTGAAGATGAAGATGCTCCAATTTCAATAACCTTGGATGACACC
AAGCCTGATGGGTCACTGCCTGCCATCATGGGCTTCATTCTTGCCCGGAAAGCTGATCGA
CTTGCTAAGCTACATAAGGAAATAAGGAAGAAGAAAATCTGTGAGCTCTATGCCAAAGTG
CTGGGATCCCAAGAAGCTTTACATCCAGTGCATTATGAAGAGAAGAACTGGTGTGAGGAG
CAGTACTCTGGGGGCTGCTACACGGCCTACTTCCCTCCTGGGATCATGACTCAATATGGA
AGGGTGATTCGTCAACCCGTGGGCAGGATTTTCTTTGCGGGCACAGAGACTGCCACAAAG
TGGAGCGGCTACATGGAAGGGGCAGTTGAGGCTGGAGAACGAGCAGCTAGGGAGGTCTTA
AATGGTCTCGGGAAGGTGACCGAGAAAGATATCTGGGTACAAGAACCTGAATCAAAGGAC
GTTCCAGCGGTAGAAATCACCCACACCTTCTGGGAAAGGAACCTGCCCTCTGTTTCTGGC
CTGCTGAAGATCATTGGATTTTCCACATCAGTAACTGCCCTGGGGTTTGTGCTGTACAAA
TACAAGCTCCTGCCACGGTCTTGA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
11812236	Li M, Hubalek F, Newton-Vinson P, Edmondson DE: High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2002 Feb;24(1):152-62.
1432104	Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46.
2764901	Weyler W: Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit. Biochem J. 1989 Jun 15;260(3):725-9.
3178846	Chen SA, Weyler W: Partial amino acid sequence analysis of human placenta monoamine oxidase A and bovine liver monoamine oxidase B. Biochem Biophys Res Commun. 1988 Oct 14;156(1):445-50.
3387449	Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8.
3418353	Hsu YP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO: Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem. 1988 Oct;51(4):1321-4.
7519662	Denney RM, Sharma A, Dave SK, Waguespack A: A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression. J Neurochem. 1994 Sep;63(3):843-56.
8584674	Denney RM: The promoter of the human monoamine oxidase A gene. Prog Brain Res. 1995;106:57-66.

# Drug_Target_1_HGNC_ID:
HGNC:6833

# Drug_Target_1_HPRD_ID:
02400

# Drug_Target_1_ID:
3941

# Drug_Target_1_Locus:
Xp11.3

# Drug_Target_1_Molecular_Weight:
59682

# Drug_Target_1_Name:
Amine oxidase [flavin-containing] A

# Drug_Target_1_Number_of_Residues:
527

# Drug_Target_1_PDB_ID:
1O5W

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01593	Amino_oxidase

# Drug_Target_1_Protein_Sequence:
>Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS

# Drug_Target_1_Reaction:
RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine

# Drug_Target_1_SwissProt_ID:
P21397

# Drug_Target_1_SwissProt_Name:
AOFA_HUMAN

# Drug_Target_1_Synonyms:
EC 1.4.3.4
MAO-A
Monoamine oxidase type A

# Drug_Target_1_Theoretical_pI:
7.96

# Drug_Target_1_Transmembrane_Regions:
498-518

#END_DRUGCARD DB01171
